New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
06:57 EDTKERX, AUXL, CBST, IRWD, ACRX, SLXP, BCRX, QCORBiotech weakness a buying opportunity, says Mizuho
Mizuho said the recent weakness in biotech will prove transient and has created buying opportunities in AcelRx (ACRX), Auxilium (AUXL), BioCryst (BCRX), Ironwood (IRWD), Keryx (KERX), Salix (SLXP), Cubist (CBST), and Questcor (QCOR).
News For ACRX;AUXL;BCRX;IRWD;KERX;SLXP;CBST;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 21, 2014
08:35 EDTAUXLBioSpecifics announces new data on XIAFLEX for Peyronie's Disease
Subscribe for More Information
November 20, 2014
15:14 EDTBCRXTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
10:02 EDTCBSTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Zoetis (ZTS) downgraded to Market Perform from Outperform at William Blair... Target (TGT) downgraded to Hold from Buy at Evercore ISI... Alexandria Real Estate (ARE) downgraded to Neutral from Outperform at RW Baird... Allscripts (MDRX) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underperform from Sector Perform at RBC Capital... Boston Properties (BXP) downgraded to Neutral from Outperform at RW Baird... Cliffs Natural (CLF) downgraded to Hold from Buy at Deutsche Bank... Cubist (CBST) downgraded to Neutral from Outperform at Credit Suisse... Denbury Resources (DNR) downgraded to Equal Weight from Overweight at Barclays... E-House (EJ) downgraded to Perform from Outperform at Oppenheimer... Owens-Illinois (OI) downgraded to Market Perform from Outperform at BMO Capital... Quality Systems (QSII) downgraded to Sector Perform from Outperform at RBC Capital... Sapient (SAPE) downgraded to Hold from Buy at Stifel... Harsco (HSC) downgraded to Hold from Buy at Argus... Credit Acceptance (CACC) downgraded to Underperform from Market Perform at JMP Securities... Liberty Media (LMCA) downgraded to Hold from Buy at Telsey Advisory.
09:02 EDTIRWDIronwood earns $15M milestone from Astellas Pharma
Ironwood Pharmaceuticals has earned a $15M development milestone payment from Astellas Pharma Inc., its partner for linaclotide in Japan. This milestone was triggered by Astellasís enrollment of the first patient in a randomized, double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with irritable bowel syndrome with constipation in Japan. Astellas expects to complete the Phase III trial in 2016. Ironwood and Astellas entered into a licensing agreement in 2009 to develop and commercialize linaclotide in Japan for the treatment of IBS-C, chronic constipation and other gastrointestinal conditions. Per the agreement, Astellas paid Ironwood a $30M upfront licensing fee. In addition to the $15M development milestone payment upon enrollment of the first patient in the Phase III trial, the agreement also includes additional development milestone payments that could total up to $30M, consisting of $15M upon filing for regulatory approval in Japan and $15M upon receipt of approval. The agreement also provides for Ironwood to receive royalties which escalate based on sales volume. Astellas also plans to expand its development of linaclotide in Japan and is entering into a Phase II clinical trial with linaclotide in adults with chronic constipation. If approved, the same royalty terms would apply.
07:43 EDTCBSTCubist downgraded at Credit Suisse
Subscribe for More Information
07:09 EDTAUXLAuxilium presents STENDRA data at SMSNA meeting
Auxilium Pharmaceuticals announced that data were presented regarding the use of STENDRA tablets for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. A post-hoc analysis of data from a placebo-controlled, Phase 4 study of STENDRA evaluated men who had at least one attempt at intercourse within approximately 15 minutes of taking the medication. The STENDRA 100 and 200mg doses demonstrated statistically significant improvement in onset of erectogenic effect at approximately 15 minutes compared to placebo, with a mean per-patient proportion of sexual attempts that resulted in at least one successful intercourse within approximately 15 minutes after dosing of 73.3% and 71.5%, respectively. Results of a study examining the proportion of men with ED who reported successful intercourse within the first three doses of STENDRA showed more than 60% of patients reported successful intercourse within the first three doses of STENDRA. This compares to about 40% with placebo. A higher percentage, or 75% for STENDRA vs. 56% for placebo, also reported success after any dose.
07:07 EDTAUXLAuxilium presents XIAFLEX for Peyronie's Disease data
Auxilium Pharmaceuticals announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS trials evaluating XIAFLEX for the treatment of Peyronie's disease, at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. Data were presented providing further evidence that PD bother is clinically significant and may be a useful measure in clinical practice when treating PD. Data were also presented suggesting that improvements in PD bother are correlated with improvements in penile curvature deformity.
06:06 EDTCBSTCubist downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
November 19, 2014
07:33 EDTAUXLEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
November 18, 2014
07:02 EDTAUXLAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information
November 17, 2014
17:19 EDTKERXKeryx announces trade name Auryxia for ferric citrate
Subscribe for More Information
08:44 EDTBCRXNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
07:49 EDTKERXKeryx to host special shareholder meeting
Subscribe for More Information
07:16 EDTCBSTMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:16 EDTCBSTCubist to invest about $400M in antibiotics R&D in 2014
Subscribe for More Information
November 16, 2014
14:48 EDTKERXKeryx announces results from Ferric Citrate study
Subscribe for More Information
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.
November 13, 2014
07:08 EDTACRXAcelRx to present positive efficacy results in Phase 3 trial of Zalviso
AcelRx Pharmaceuticals will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery at the American Society of Regional Anesthesia and Pain Medicine 13th Annual Pain Medicine Meeting on November 13th to November 16th in San Francisco. Data from the sublingual sufentanil tablet system development program highlights efficacy across various demographic populations
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use